Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Eesti - eesti - Ravimiamet

pharma nord aps - melatoniin - õhukese polümeerikattega tablett - 3mg 30tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - atorvastatiin - õhukese polümeerikattega tablett - 20mg 50tk; 20mg 98tk; 20mg 20tk; 20mg 7tk; 20mg 56tk; 20mg 4tk; 20mg 10tk; 20mg 14tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kvetiapiin - õhukese polümeerikattega tablett - 25mg 30tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - atorvastatiin - õhukese polümeerikattega tablett - 10mg 20tk; 10mg 56tk; 10mg 100tk; 10mg 500tk; 10mg 30tk; 10mg 10tk; 10mg 50tk; 10mg 4tk; 10mg 98tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - atorvastatiin - õhukese polümeerikattega tablett - 40mg 10tk; 40mg 30tk; 40mg 200tk; 40mg 500tk; 40mg 56tk; 40mg 28tk; 40mg 14tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kvetiapiin - õhukese polümeerikattega tablett - 300mg 90tk; 300mg 60tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kvetiapiin - õhukese polümeerikattega tablett - 200mg 60tk

Eesti - eesti - Ravimiamet

pharmaceutical works polpharma s.a. - kvetiapiin - õhukese polümeerikattega tablett - 100mg 90tk

Eesti - eesti - Ravimiamet

woerwag pharma gmbh & co. kg - sitagliptiin - õhukese polümeerikattega tablett - 50mg 98tk; 50mg 10tk; 50mg 28tk; 50mg 14tk; 50mg 100tk